Advertisement
Screener

Acumen Pharmaceuticals, Inc. (ABOS) Quick Ratio

2.8 / 5 stars · 68/120 Roast Me

Acumen Pharmaceuticals, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • Acumen Pharmaceuticals, Inc. quick ratio for the quarter ending 2026-06-30 was 2.35, a 59.21% decline year-over-year.
  • Acumen Pharmaceuticals, Inc. quick ratio for the quarter ending 2026-03-31 was 4.39, a 43.11% decline year-over-year.
  • Acumen Pharmaceuticals, Inc. quick ratio for the quarter ending 2025-12-31 was 3.89, a 37.33% decline year-over-year.
  • Acumen Pharmaceuticals, Inc. quick ratio for the quarter ending 2025-09-30 was 5.77, a 42.68% decline year-over-year.
  • Acumen Pharmaceuticals, Inc. quick ratio for fiscal 2025 was 3.89, a 37.33% decline from fiscal 2024.
  • Acumen Pharmaceuticals, Inc. quick ratio for fiscal 2024 was 6.21, a 66.90% decline from fiscal 2023.
  • Acumen Pharmaceuticals, Inc. quick ratio for fiscal 2023 was 18.77, a 17.42% decline from fiscal 2022.
  • Acumen Pharmaceuticals, Inc. quick ratio for fiscal 2022 was 22.73, a 39.76% decline from fiscal 2021.
Available history
2021-12-31 to 2026-06-30
Data captured

Historical Quick Ratio

DateQuick RatioQuick assetsCurrent liabilities
2026-06-302.35$110.2M$46.85M
2026-03-314.39$128.4M$29.23M
2025-12-313.89$116.87M$30.01M
2025-09-305.77$126.61M$21.96M
2025-06-305.77$143.37M$24.86M
2025-03-317.72$149.15M$19.32M
2024-12-316.21$171.56M$27.61M
2024-09-3010.06$200.34M$19.91M
2024-06-3016.95$260.47M$15.37M
2024-03-3129.81$252.51M$8.47M
2023-12-3118.77$243.52M$12.97M
2023-09-3035.33$215.43M$6.1M
2022-12-3122.73$177.61M$7.81M
2022-09-3030.27$200.19M$6.61M
2022-06-3036.99$189.91M$5.13M
2022-03-3148.04$189.09M$3.94M
2021-12-3137.74$194.24M$5.15M

Annual Quick Ratio

DateQuick RatioQuick assetsCurrent liabilities
2025-12-313.89$116.87M$30.01M
2024-12-316.21$171.56M$27.61M
2023-12-3118.77$243.52M$12.97M
2022-12-3122.73$177.61M$7.81M
2021-12-3137.74$194.24M$5.15M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48